

Highly Specialised Technology Committee [HST] Interests Register

Topic: Selinexor with bortezomib and low-dose dexamethasone for treating relapsed refractory multiple myeloma [ID3797]

Publication Date: 15/05/2024

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Comments
Stuart Mealing	HST Committee Member	Financial Interests	Other members of my company have done work for Sanofi in the same underlying disease, about four years ago.	07/03/2024	It was agreed that his declarations would not prevent Stuart Mealing from participating in discussions on this appraisal.
Emtiyaz Chowdhury	HST Committee Member	Non-financial professional interests	I have provided access consulting services to Menarini over the last 12 months on behalf of my employer Parexel. The activities pertained to two technologies, Elzonris for patients with BPCDN and obicetrapic for patients with uncontrolled LDL levels. Menarini do not have any agreed services with my team to provide support for this technology.	07/03/2024	It was agreed that his declarations would not prevent Stuart Mealing from participating in discussions on this appraisal.
Neil Rabin	Clinical Expert	Financial Interests	o Celgene (BMS). Support to attend conferences, speak at educational meetings and advisory boards.	07/03/2024	It was agreed that his declaration would not prevent Neil Rabin from

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Comments
			<ul style="list-style-type: none"> o Janssen-Cilag. Support to attend conferences, speak at educational meetings and advisory boards., o Menirini-Stemline. Support to attend conference and advisory boards. o Takeda. Support to attend conferences, speak at educational meetings and advisory boards. o Sanofi. Speak at educational meetings and advisory board. o Amgen. Advisory board. o Executive member of the UK Myeloma Forum (provides education and advocates on behalf of myeloma doctors in the UK). 		providing expert advice to the committee.
Karthik Ramasamy	Clinical Expert	Non-financial professional interests	<ul style="list-style-type: none"> o Executive Member of UK Myeloma society and Trustee for myeloma charity o Has served as an advisor and has received speaker honoraria from AbbVie, Adaptive Biotechnologies, Amgen, Celgene (Bristol Myers Squibb), EUSA Pharma/ Recordati, Glaxo Smith Kline, Janssen, 	07/03/2024	It was agreed that his declaration would not prevent Karthik Ramasamy from providing expert advice to the committee.

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Comments
			Karyopharm, Oncopeptides, Pfizer, Sanofi, and Takeda. o Conference Travel grants from Takeda, Janssen, Menarini Stemline.		